<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02922426</url>
  </required_header>
  <id_info>
    <org_study_id>ALK3831-A108</org_study_id>
    <nct_id>NCT02922426</nct_id>
  </id_info>
  <brief_title>An Insulin Sensitivity Study in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Parallel-Group Study in Healthy Subjects to Characterize Insulin Sensitivity and Lipid Metabolism in Response to Treatment With ALKS 3831 and Olanzapine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkermes, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkermes, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will characterize insulin sensitivity in response to treatment with ALKS 3831,
      olanzapine, and placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">July 20, 2017</completion_date>
  <primary_completion_date type="Actual">July 20, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in blood glucose concentrations</measure>
    <time_frame>21 days</time_frame>
    <description>Differences will be compared among treatment groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in insulin concentrations</measure>
    <time_frame>21 days</time_frame>
    <description>Differences will be compared among treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events (AEs)</measure>
    <time_frame>24 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>ALKS 3831</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral, bilayer tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral, bilayer tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral, bilayer tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALKS 3831</intervention_name>
    <description>Daily dosing for 21 consecutive days</description>
    <arm_group_label>ALKS 3831</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Daily dosing for 21 consecutive days</description>
    <arm_group_label>Olanzapine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Daily dosing for 21 consecutive days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index (BMI) between 18.0 and &lt; 25.0 kg/m^2 at screening and randomization

          -  No prior history of regular smoking or nicotine use

          -  Women of child-bearing potential should be on stable regimens of oral contraceptives
             for at least 2 months prior to screening

          -  Subjects must be willing to avoid a regular exercise regimen from screening through
             the end of the treatment period

          -  Additional criteria may apply

        Exclusion Criteria:

          -  Has current evidence or history of any clinically significant medical or psychiatric
             condition or observed abnormality

          -  Is currently pregnant or breastfeeding, or is planning to become pregnant during the
             study

          -  Has a lifetime history of diabetes

          -  Has a known risk of narrow-angle glaucoma

          -  Has a clinically significant illness within 30 days prior to screening or admission to
             the clinic

          -  Has a history of dependence on any substance other than caffeine

          -  Has a current or anticipated need for prescribed opioid medication (eg, planned
             surgery) during the study period

          -  Has a positive urine drug screen for drugs of abuse at screening or admission to the
             study site

          -  Has had a serious infection (eg, pneumonia or septicemia) within the 3 months prior to
             screening or admission to the clinic

          -  Has had any vaccinations in the 4 weeks prior to screening or admission to the clinic

          -  Chronic use of non-steroid anti-inflammatory drugs (NSAIDs) and acetaminophen, except
             for low-dose Aspirin is not allowed

          -  Use of new prescription and non-prescription drugs, as well as dietary/nutritional
             supplements within 3 weeks preceding the first dosing of study drugs, unless approved
             by Investigator

          -  Has prior use of any antipsychotic medication, including on and off label uses

          -  Additional criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David McDonnell, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alkermes, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2016</study_first_submitted>
  <study_first_submitted_qc>September 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2016</study_first_posted>
  <last_update_submitted>August 18, 2017</last_update_submitted>
  <last_update_submitted_qc>August 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALKS 3831</keyword>
  <keyword>Samidorphan</keyword>
  <keyword>Olanzapine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

